DRKS00013587已完成不适用
CLEVER: CLadribine tablets - EValuation of therapy satisfaction - CLEVER
Merck Serono GmbH, Germany0 个研究点目标入组 510 人开始时间: 2018年1月16日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 510
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •· Patients (male or female) aged 18 years and over
- •· All patients eligible to receive Cladribine tablets as per registered label
- •· Patients using Cladribine tablets for the first time.
- •- Inclusion to the NIS can occur at treatment initiation or within 24 weeks after treatment initiation
- •· Signed informed consent
排除标准
- •· Existing pregnancy or lactation
- •· Contraindications to use of Cladribine tablets
- •according to the Summary of Product Characteristics
研究者
相似试验
已完成
3 期
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)Multiple Sclerosis, Relapsing-RemittingNCT00213135EMD Serono1,326
进行中（未招募）
3 期
ong term monitoring of multiple sclerosis patients on cladribine treatmentNeurological - Multiple sclerosisMultiple SclerosisACTRN12619000257167John Hunter Hospital of Hunter New England Local Health District150
进行中（未招募）
不适用
Clinical Trial with Cladribine (2-CDA) and Pegylated Interpheron Alfa-2a in patients with advanced systemic mastocytosis carrying D816V KIT mutation (or different mutations involving exon 17 of KIT).EUCTR2012-000797-35-ESHospital Virgen de la Salud, Toledo (Spain).
已完成
不适用
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)Multiple SclerosisNCT03933202EMD Serono Research & Development Institute, Inc.291
已完成
不适用
A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)Multiple SclerosisNCT03933215EMD Serono Research & Development Institute, Inc.100